(Q36682458)

15 August 2017

1 reference

title

Disease-modifying trials in Alzheimer's disease: a European task force consensus (English)

1 reference

15 August 2017

0 references

3

Cristina Sampaio

1 reference

15 August 2017

1

Bruno Vellas

1 reference

15 August 2017

Sandrine Andrieu

2

1 reference

15 August 2017

Gordon Wilcock

series ordinal

4

1 reference

15 August 2017

European Task Force group

series ordinal

5

1 reference

15 August 2017

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

56-62

1 reference

Treatment of Alzheimer's disease: current status and new perspectives.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Immunotherapy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

1 reference

7 January 2021

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

An efficient multi‐stage, single‐arm Phase II futility design for ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

A new clinical scale for the staging of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Relatives of the impaired elderly: correlates of feelings of burden.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Statistical issues in interpreting clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

A comparison of imputation methods in a longitudinal randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

CSF markers for incipient Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

The ethical analysis of risk

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970677-9

7 January 2021

10.1016/S1474-4422(06)70677-9

Identifiers

DOI

1 reference

15 August 2017

1 reference